Amendments to the Claims:

1. (currently amended) A recombinant nucleotide construct composed of the sequence of SEQ ID NO: 1 ~~or a species equivalent and~~ encoding a mutated human prolactin, wherein the expression of the sequence results in a mimic of a phosphorylated human prolactin ~~corresponding to a selected species~~, the mimic being capable of antagonizing growth promoting effects of non-phosphorylated human prolactin ~~in the selected species~~, the mimic being mutated by an aspartate or glutamate residue substitution at serine 179 ~~or its selected species equivalent~~.

2. (canceled)

3. (currently amended) The nucleotide sequence as in claim 1 wherein the serine is mutated by ~~an aspartate or~~ a glutamate residue substitution.

4. (previously presented) The nucleotide sequence as in claim 1 wherein the serine mutation is by an aspartate residue substitution.

5. (original) A construct comprising the nucleotide of claim 3 or 4 operatively linked with an expression vector.

6. (original) The construct as in claim 5 wherein the expression vector is mammalian, viral or bacterial.

9. (previously presented) A composition comprising:

a human phosphorylated prolactin mimic, the mimic in an amount effective to antagonize growth promoting effects of non-phosophorylated human prolactin, the mimic being expressible by SEQ ID NO:1, being mutated at serine 179 and being substantially free of non-phosphorylated human prolactin; and

a pharmaceutically suitable carrier in which the mimic is admixed.

10. (original) The composition as in claim 9 wherein the serine 179 is substituted by an aspartate or glutamate residue.

11. (original) The composition as in claim 9 wherein the serine 179 is substituted by an aspartate residue.